Navigation Links
Viteava Pharmaceuticals Executes Worldwide Exclusive License
Date:11/19/2013

redient, EGCG, to design commercially-viable drug candidates."

Viteava Pharmaceuticals will focus on the development of novel approaches to manage cancer and related conditions. It has identified VPE001, a prodrug of EGCG with improved bioavailability and potency, as its lead drug candidate expected to enter clinical development in 2015. Initial clinical indications may include the treatment of uterine fibroids and/or delaying the progression of cancer in high-risk, early-stage chronic lymphocytic leukemia patients.

Professor Dou added, "My laboratory was the first to identify inhibition of proteasomal chymotrypsin-like activity as an important mechanism of action of EGCG. We also know that EGCG can also affect, albeit to a lesser extent, other important pathways, such as PI3K/Akt/mTOR signaling. Viteava's drug candidates target diseases where these pathways are dysregulated."

The company's strategy focuses principally on clinical indications where green tea extracts have been demonstrated to elicit biological responses in human studies. Viteava's drug candidates are designed to improve these treatment regimens and achieve better clinical outcomes, while retaining a high level of safety. By regulating multiple pathways important to the progression of diseases such as cancer, Viteava's drug candidates are expected to provide advantages over more potent and more selective drugs that usually only elicit temporary responses together with a high level of toxicity.

Robert Foldes added that "our strategy certainly reduces clinical development risk while targeting significant medical conditions lacking efficacious long-term pharmaceutical interventions and where we can significantly improve standard-of-care."

About Viteava Pharmaceuticals Inc.

Viteava is a start-up drug development company dedicated to improving the treatment and management of cancer and related conditions to enhance qualit
'/>"/>

SOURCE Viteava Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Biotest Pharmaceuticals Honored with the 2013 Greater Miami Chamber of Commerce International Business Leadership Award for "Business Expansion"
2. GW Pharmaceuticals plc Reports 2013 Q4 and Full Year Financial Results
3. Isis Pharmaceuticals Reports Fifth Positive Phase 2 Data Set for ISIS-APOCIII Rx Showing Significant Reductions in Triglyceride and ApoC-III Levels
4. Hi-Tech Pharmaceuticals Sues The FDA For "Bullying Tactics"
5. GW Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference
6. Lumena Pharmaceuticals Receives Positive Opinion for Orphan Drug Designation in the European Union for LUM001 in Four Rare Liver Diseases
7. RXi Pharmaceuticals Corporation and Ethicor Ltd. Announce the Signing of a Distribution Agreement for RXI-109 in the European Union under the "Specials" Provision
8. Isis Pharmaceuticals Reports Positive Phase 1 Data Demonstrating ISIS-APO(a) Rx Produces Significant Reductions in Lp(a) Levels
9. Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes
10. Valeant Pharmaceuticals Announced Redemption Of $450 Million Aggregate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016
11. ANI Pharmaceuticals To Present At Oppenheimer 24th Annual Healthcare Conference On December 10, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 /PRNewswire/ ... market research report is available in ... Guidebook for Application and Approval of ... to Practices (2014 Edition) ... Now, Chinese regulations on ...
(Date:8/27/2014)... R.I. , Aug. 27, 2014  CVS Caremark ... entered into a new clinical affiliation with MedStar Health, ... Maryland and the ... to high-quality, affordable health care services for patients. Through ... have access to clinical support, medication counseling, chronic disease ...
(Date:8/27/2014)... , Aug. 27, 2014 Amgen (NASDAQ: ... and Drug Administration (FDA) has granted priority review designation ... (HF). Ivabradine is an oral drug that inhibits the ... the sinoatrial node, the body,s cardiac pacemaker. 1 ... effects on myocardial contractility or ventricular repolarization. 1 ...
Breaking Medicine Technology:Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 2Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 3Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 4Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 5Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 6Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 7Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 8Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 9Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 10CVS Caremark Announces New Clinical Affiliation with MedStar Health 2CVS Caremark Announces New Clinical Affiliation with MedStar Health 3FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 2FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 3FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 4FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 5FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 6FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 7
... Inc. (NASDAQ - YDNT) today announced that it will broadcast ... web cast conference call on Thursday, October 20, 2011 at ... call will be available through InterCall at http://tinyurl.com/YI-Quarter32011 . ... through the Company,s website, www.ydnt.com . ...
... CEO Yaacov Shoham today announced the following order. ... many new markets, including Australia-a most important market for IDenta,s ... 2000 detectors from the Australian representative GK Solutions Pty ... several months we have been in continuous contact with this ...
Cached Medicine Technology:Young Innovations, Inc. Provides 3rd Quarter Conference Call Details 2International Drug & Explosives Detection Company IDenta Corp. Receives Order From Australia 2
(Date:8/27/2014)... BRIC Laparoscopes Market Outlook to 2020 , ... data on the BRIC Laparoscopes market. The report provides ... and average prices (in US dollars) within market segments ... Video Laparoscopes), Robotic Surgical Systems and Rigid Tip Non-Video ... the patient with laparoscopic surgery versus the more common, ...
(Date:8/27/2014)... ANS is pleased to announce the availability ... the treatment of recurrent glioblastoma (GBM). Experts at ANS ... and will begin extending this new treatment option for ... a portable, non-invasive anti-mitotic system approved for use in ... It is a treatment option for patients with recurrent ...
(Date:8/27/2014)... Ticket Down is a dependable source for authentic Brazil ... The Brazilian national soccer team will tangle with the ... Stadium in Miami Gardens, Florida. The two South American ... earlier this year when Brazil got the 2-1 win, but ... announced earlier this week that Neymar would return from injury ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Power morcellator ... U.S. courts on behalf of women who allegedly experienced ... Bernstein Liebhard LLP reports. According to court documents, one ... 18th in the U.S. District Court, Northern District of ... claims the use of a power morcellator manufactured Karl ...
(Date:8/27/2014)... Charlotte, NC (PRWEB) August 27, 2014 ... intensity focused ultrasound (HIFU), announced record-setting sales of 15 ... a steady worldwide surge in demand for the company’s ... see the results our team has achieved over the ... the Fall, which has historically been our most active ...
Breaking Medicine News(10 mins):Health News:Laparoscopes & Endoscopic Reprocessors Market in BRIC (Brazil, Russia, India & China) to 2020 Report Available at RnRMarketResearch.com 2Health News:Laparoscopes & Endoscopic Reprocessors Market in BRIC (Brazil, Russia, India & China) to 2020 Report Available at RnRMarketResearch.com 3Health News:Laparoscopes & Endoscopic Reprocessors Market in BRIC (Brazil, Russia, India & China) to 2020 Report Available at RnRMarketResearch.com 4Health News:Atlantic NeuroSurgical Specialists (ANS) Announces Availability of New Therapy for Brain Cancer 2Health News:Atlantic NeuroSurgical Specialists (ANS) Announces Availability of New Therapy for Brain Cancer 3Health News:Brazil vs. Colombia Tickets in Miami, FL: Ticket Down Cuts Ticket Prices on World Cup Rematch of Colombia vs. Brazil at Sun Life Stadium in Miami on Sept. 5th 2Health News:Brazil vs. Colombia Tickets in Miami, FL: Ticket Down Cuts Ticket Prices on World Cup Rematch of Colombia vs. Brazil at Sun Life Stadium in Miami on Sept. 5th 3Health News:Power Morcellator Lawsuit Alleges Storz Morcellator Caused Spread of Aggressive Uterine Cancer, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Lawsuit Alleges Storz Morcellator Caused Spread of Aggressive Uterine Cancer, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Lawsuit Alleges Storz Morcellator Caused Spread of Aggressive Uterine Cancer, Bernstein Liebhard LLP Reports 4Health News:SonaCare Medical Announces Twelve Months Sales Results of Fifteen HIFU Devices 2
... Barbara, Calif.) Scientists at UC Santa Barbara have discovered ... disease and may open up new targets for drug discovery. ... culture to finding out how they work with mice. ... Journal of Neuroscience , the scientists describe important activities of ...
... LOUIS, Feb. 5 The most recent survey ... the physician shortage,is taking a toll on hospital ... changing tactics and personnel to combat the lack,of ... Louis-based PracticeMatch,Services has officially released results from their ...
... Ill., Feb 5 Stephens Media LLC of,Las ... America of,Lisle, Illinois to deliver Surgery Benefit Management ... superior quality surgical care and,personal savings through Healthplace ... To date, the Healthplace,Surgery Benefit(TM) is the ...
... found 2 popular cholesterol-lowering drugs had little effect on ... have clearly proven their mettle against heart disease, but ... a new animal study shows. , "We certainly didn,t ... in the division of cancer prevention at the National ...
... leading companies have developed and staffed an internal ... of economic adversity, as costs are scrutinized, the ... questioned. Although internal consulting organizations are typically created ... and take on additional responsibilities supporting important executive ...
... Inc. (Nasdaq: MSON ), a developer of ... is used for the ablation of tumors and worldwide ... release second quarter fiscal year 2009 financial results on ... President and Chief Executive Officer and Richard Zaremba, Senior ...
Cached Medicine News:Health News:UCSB scientists make headway in understanding Alzheimer's disease 2Health News:UCSB scientists make headway in understanding Alzheimer's disease 3Health News:PracticeMatch: Healthcare Survey Defines Physician Recruitment Challenges 2Health News:Stephens Media LLC Partners With Healthplace America to Enhance Employee Healthcare Benefits With Quality and Savings for Surgery 2Health News:Stephens Media LLC Partners With Healthplace America to Enhance Employee Healthcare Benefits With Quality and Savings for Surgery 3Health News:Stephens Media LLC Partners With Healthplace America to Enhance Employee Healthcare Benefits With Quality and Savings for Surgery 4Health News:Statins Don't Cut Cancer Risk 2Health News:New Study Provides Benchmarks for Best Practices for Valuing Internal Consulting Organizations 2Health News:Misonix Schedules Second Quarter Fiscal Year 2009 Financial Results Conference Call; February 9, 2009 at 4:30 P.M. Eastern 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: